Basilea announces collaboration to study derazantinib and atezolizumab (Tecentriq?) in urothelial cancer
Basel, Switzerland,??- Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it entered into a collaboration with Roche (SIX: RO, ROG) to explore a combination of Basilea's derazantinib and Roche's PD-L1-blocking immune-checkpoint inhibitor atezolizumab (Tecentriq?) in patients with urothelial cancer. Basilea expects to start a biomarker-driven multi-cohort phase 1/2 study mid-2019.